ellipticine has been researched along with histidine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elsea, SH; Hsiung, Y; Nitiss, JL; Osheroff, N | 1 |
| Bennett, WF; Chen, P; Chu, D; Ding, Y; Fan, HY; Heerklotz, H; Karttunen, M; Li, J; Lu, S; Ouyang, PK; Wu, Y; Xu, W; Yuan, Y; Zhang, L; Zhao, D; Zheng, T | 1 |
| Chen, P; Ding, Y; Gui, Z; Jin, G; Martz, M; Ouyang, P; Wang, F; Wang, T; Xu, J; Zhang, L | 1 |
3 other study(ies) available for ellipticine and histidine
| Article | Year |
|---|---|
A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine.
Topics: Amino Acid Sequence; Animals; Anti-Infective Agents; DNA Topoisomerases, Type II; Drug Resistance; Ellipticines; Fluoroquinolones; Histidine; Humans; Kinetics; Mice; Molecular Sequence Data; Mutagenesis, Site-Directed; Point Mutation; Quinolones; Recombinant Proteins; Saccharomyces cerevisiae; Sequence Homology, Amino Acid; Topoisomerase II Inhibitors; Tyrosine | 1995 |
Design and Characterization of a Multifunctional pH-Triggered Peptide C8 for Selective Anticancer Activity.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Ellipticines; Histidine; Humans; Hydrogen-Ion Concentration; Liposomes; Mice; Nanostructures; NIH 3T3 Cells; Peptides | 2015 |
Histidine-Rich Cell-Penetrating Peptide for Cancer Drug Delivery and Its Uptake Mechanism.
Topics: A549 Cells; Amino Acid Sequence; Animals; Antineoplastic Agents; Cell Survival; Cell-Penetrating Peptides; CHO Cells; Cricetulus; Drug Carriers; Drug Liberation; Ellipticines; Histidine; Humans; Hydrogen-Ion Concentration; Lipopeptides; Nanostructures | 2019 |